NEW DELHI: Pune-based Krsnaa Diagnostics, an integrated diagnostics provider, announced plans to acquire nearly 24% stake in start-up Apulki Healthcare for exclusive rights to provide diagnostics services.
Apulki Healthcare, incorporated in 2022, is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology, primarily under the public-private partnership mode, says a company statement.
The acquisition will be completed within the next three months.
Under this collaboration, Krsnaa Diagnostics will become the exclusive diagnostics partner for Apulki’s state-of-the-art cancer and cardiac hospitals for the next 30+ years. This ensures Krsnaa’s sustained leadership in the high-growth oncology and cardiac diagnostic segments, with access to Apulki’s planned network of 10+ hospitals across India.
By offering a comprehensive suite of cutting-edge diagnostic technologies—including MRI, PET CT, Cardiac CT, and Advanced Pathology—available 24×7 under one roof, Krsnaa and Apulki will provide seamless, world-class diagnostic services for patients undergoing cancer and cardiac treatment.
